Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.70 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656936 | 0.94 | DRD4 (0.62) | DRD4DRD2DRD3KDM4EGFER | |
| SCHEMBL5629449 | 0.91 | DRD4 (0.70) | DRD4DRD2DRD3KDM4EGFER | |
| SCHEMBL5625462 | 0.89 | DRD4 (0.68) | DRD4DRD2DRD3KDM4EGFER | |
| SCHEMBL15800693 | 0.85 | CHRNB2 (0.77) | DRD4DRD2DRD3KDM4EMAPK1 | |
| SCHEMBL8309126 | 0.84 | DRD4 (0.69) | DRD4DRD2DRD3KDM4EMAPT | |
| SCHEMBL6031812 | 0.83 | DRD4 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL12261943 | 0.82 | DRD4 (0.77) | DRD4DRD2DRD3POLB | |
| SCHEMBL1669246 | 0.82 | DRD4 (0.77) | DRD4DRD2DRD3KDM4EPOLB | |
| SCHEMBL16026435 | 0.79 | CHRNB2 (0.85) | DRD4DRD2DRD3KDM4EGFER | |
| SCHEMBL20847693 | 0.79 | DRD4 (0.61) | DRD4DRD2DRD3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785696-B1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| EP-2785696-A1 | NOVEL COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2014-10-08 | — | — | EP | disclosed |
| US-8822464-B2 | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| WO-2013079460-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20130137688-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
| EP-0918770-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | AstraZeneca AB (SE) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998001447-A1 | PYRIDYL-PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | ZENECA LIMITED (GB) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137688-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | DRD4 250/4885DRD2 152/4885DRD3 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.